台耀利多:飆股的故事台耀母以子貴吸引外資
Provide From Google
![4746 台耀](https://i0.wp.com/api.multiavatar.com/4746+%E5%8F%B0%E8%80%80-+%E4%BB%8A%E6%97%A5%E5%8D%B3%E6%99%82%E8%82%A1%E5%83%B9%E8%88%87%E8%B5%B0%E5%8B%A2%E5%9C%96%EF%BD%9CCMoney+%E8%82%A1%E5%B8%82%E7%88%86%E6%96%99%E5%90%8C%E5%AD%B8%E6%9C%83.png?apikey=viVnb6N20jclO8)
4746 台耀
https://www.cmoney.tw
台耀(4746)今日即時股價與走勢圖,提供台耀(4746)股價、成交量、漲跌幅與總單量等第一手消息,還有眾多股市達人協助回答你的台耀持股疑問。
Provide From Google
![4746台耀股票的7個亮點與3個風險,生技醫療產業](https://i0.wp.com/api.multiavatar.com/4746%E5%8F%B0%E8%80%80%E8%82%A1%E7%A5%A8%E7%9A%847%E5%80%8B%E4%BA%AE%E9%BB%9E%E8%88%873%E5%80%8B%E9%A2%A8%E9%9A%AA%EF%BC%8C%E7%94%9F%E6%8A%80%E9%86%AB%E7%99%82%E7%94%A2%E6%A5%AD.png?apikey=viVnb6N20jclO8)
4746台耀股票的7個亮點與3個風險,生技醫療產業
https://statementdog.com
4746台耀現金股利殖利率0.98%,近五年填息機率50%。歷年現金股利、股票股利、除權息日期、填息花費 ... 台耀只通過17% 排除地雷股檢查項目,顯示公司財務體質風險高。
Provide From Google
![〈焦點股〉台耀今年毛利率逐季增股價攻上漲停鎖住](https://i0.wp.com/api.multiavatar.com/%E3%80%88%E7%84%A6%E9%BB%9E%E8%82%A1%E3%80%89%E5%8F%B0%E8%80%80%E4%BB%8A%E5%B9%B4%E6%AF%9B%E5%88%A9%E7%8E%87%E9%80%90%E5%AD%A3%E5%A2%9E%E8%82%A1%E5%83%B9%E6%94%BB%E4%B8%8A%E6%BC%B2%E5%81%9C%E9%8E%96%E4%BD%8F.png?apikey=viVnb6N20jclO8)
〈焦點股〉台耀今年毛利率逐季增股價攻上漲停鎖住
https://news.cnyes.com
台股陷萬七保衛戰,資金流向生技族群,其中原料藥廠台耀(4746-TW) 今年營運轉佳,隨著旗下磷酸鹽客戶市占率擴大,新產能也將加入投產,全年毛利率逐季 ...
Provide From Google
![【台股研究報告】台耀(4746)主力產品2025年前訂單滿手](https://i0.wp.com/api.multiavatar.com/%E3%80%90%E5%8F%B0%E8%82%A1%E7%A0%94%E7%A9%B6%E5%A0%B1%E5%91%8A%E3%80%91%E5%8F%B0%E8%80%80%284746%29%E4%B8%BB%E5%8A%9B%E7%94%A2%E5%93%812025%E5%B9%B4%E5%89%8D%E8%A8%82%E5%96%AE%E6%BB%BF%E6%89%8B.png?apikey=viVnb6N20jclO8)
【台股研究報告】台耀(4746)主力產品2025年前訂單滿手
https://www.money.com.tw
台耀2022年營收37.7億元,較去年成長19.8%,全年EPS 3.4元,年減68.9%,變動主要來自於台康生評價利益影響業外收入,台康生2021年認列評價利益約12.0億元 ...
Provide From Google
![存股OK!7月生技雙利多專家推5檔配息穩](https://i0.wp.com/api.multiavatar.com/%E5%AD%98%E8%82%A1OK%EF%BC%817%E6%9C%88%E7%94%9F%E6%8A%80%E9%9B%99%E5%88%A9%E5%A4%9A%E5%B0%88%E5%AE%B6%E6%8E%A85%E6%AA%94%E9%85%8D%E6%81%AF%E7%A9%A9.png?apikey=viVnb6N20jclO8)
存股OK!7月生技雙利多專家推5檔配息穩
https://ctee.com.tw
分析師則看好原料藥領域,點名神隆、中化生、旭富、台耀及生泰等5家,獲利與配息表現穩健,身邊不少生物博士朋友願意長期持有,作為存股配置的一環。